Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 9—September 2015
THEME ISSUE
Emerging Infections Program
Emerging Infections Program

Twenty Years of Active Bacterial Core Surveillance

Gayle LangleyComments to Author , William Schaffner, Monica M. Farley, Ruth Lynfield, Nancy M. Bennett, Arthur L. Reingold, Ann Thomas, Lee H. Harrison, Megin Nichols, Susan Petit, Lisa Miller, Matthew R. Moore, Stephanie J. Schrag, Fernanda C. Lessa, Tami H. Skoff, Jessica R. MacNeil, Elizabeth Briere, Emily J. Weston, and Chris Van Beneden
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (G. Langley, M.R. Moore, S.J. Schrag, F.C. Lessa, T.H. Skoff, J.R. MacNeil, E.C. Briere, E.J. Weston, C. Van Beneden); Vanderbilt University School of Medicine, Nashville, Tennessee, USA (W. Schaffner); Emory University School of Medicine and The Atlanta VA Medical Center, Atlanta (M.M. Farley); Minnesota Department of Health, St. Paul, Minnesota, USA (R. Lynfield); University of Rochester, Rochester, New York, USA (N.M. Bennett); University of California, Berkley, California, USA (A. Reingold); Oregon Department of Human Services, Portland, Oregon, USA (A. Thomas); Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (L.H. Harrison); New Mexico Department of Health, Santa Fe, New Mexico, USA (M. Nichols); Connecticut Department of Public Health, Hartford, Connecticut, USA (S. Petit); Colorado Department of Public Health and Environment, Denver, Colorado, USA (L. Miller)

Main Article

Figure 4

Incidence of invasive methicillin-resistant Staphylococcus aureus (MRSA) (defined as MRSA isolated from a normally sterile source) infections, by epidemiologic category, Active Bacterial Core surveillance, United States, 2005–2011 (20).

Figure 4. Incidence of invasive methicillin-resistant Staphylococcus aureus (MRSA) (defined as MRSA isolated from a normally sterile source) infections, by epidemiologic category, Active Bacterial Core surveillance, United States, 2005–2011 (20).

Main Article

References
  1. Centers for Disease Control and Prevention. Preventing emerging infectious diseases: a strategy for the 21st century. MMWR Recomm Rep. 1998;47(RR-15):1–14 .PubMedGoogle Scholar
  2. Pinner  RW, Rebmann  CA, Schuchat  A, Hughes  JM. Disease surveillance and the academic, clinical, and public health communities. Emerg Infect Dis. 2003;9:781–7. DOIPubMedGoogle Scholar
  3. Fridkin  SK, Hageman  JC, Morrison  M, Sanza  LT, Como-Sabetti  K, Jernigan  JA, Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436–44. DOIPubMedGoogle Scholar
  4. Centers for Disease Control and Prevention. Legionellosis—United States, 2000–2009. MMWR Morb Mortal Wkly Rep. 2011;60:1083–6 .PubMedGoogle Scholar
  5. American Academy of Pediatrics. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn: Guidelines for prevention of group B streptococcal (GBS) infection by chemoprophylaxis. Pediatrics. 1992;90:775–8 .PubMedGoogle Scholar
  6. American Congress of Obstetricians and Gynecologists. Group B streptococcal infections in pregnancy. ACOG Technical Bulletin Number 170–July 1992. Int J Gynaecol Obstet. 1993;42:55–9 .PubMedGoogle Scholar
  7. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Recomm Rep. 1996;45(RR-7):1–24 .PubMedGoogle Scholar
  8. Schrag  SJ, Zell  ER, Lynfield  R, Roome  A, Arnold  KE, Craig  AS, A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med. 2002;347:233–9. DOIPubMedGoogle Scholar
  9. Schrag  SJ, Gorwitz  R, Fultz-Butts  K, Schuchat  A. Prevention of perinatal group B streptococcal disease. MMWR Recomm Rep. 2002;51(RR-11):1–22.PubMedGoogle Scholar
  10. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1–36.
  11. Robinson  KA, Rothrock  G, Phan  Q, Sayler  B, Stefonek  K, Van Beneden  C, Risk for severe group A streptococcal disease among patients' household contacts. Emerg Infect Dis. 2003;9:443–7. DOIPubMedGoogle Scholar
  12. Chuang  I, Van Beneden  C, Beall  B, Schuchat  A. Population-based surveillance for postpartum invasive group A Streptococcus infections, 1995–2000. Clin Infect Dis. 2002;35:665–70. DOIPubMedGoogle Scholar
  13. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis. 2002;35:950–9. DOIPubMedGoogle Scholar
  14. Jordan  HT, Richards  CL Jr, Burton  DC, Thigpen  MC, Van Beneden  CA. Group A streptococcal disease in long-term care facilities: descriptive epidemiology and potential control measures. Clin Infect Dis. 2007;45:742–52. DOIPubMedGoogle Scholar
  15. Thigpen  MC, Richards  CL Jr, Lynfield  R, Barrett  NL, Harrison  LH, Arnold  KE, Invasive group A streptococcal infection in older adults in long-term care facilities and the community, United States, 1998–2003. Emerg Infect Dis. 2007;13:1852–9. DOIPubMedGoogle Scholar
  16. Klevens  RM, Morrison  MA, Nadle  J, Petit  S, Gershman  K, Ray  S, Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763–71. DOIPubMedGoogle Scholar
  17. Centers for Disease Control and Prevention. Management of multidrug-resistant organisms in healthcare settings. 2006 [cited 2013 Nov 4]. http://www.cdc.gov/hicpac/pdf/guidelines/MDROGuideline2006.pdf
  18. Association for Professionals in Infection Control and Epidemiology. . Guide to the elimination of Methicillin-Resistant Staphylococcus aureus (MRSA) Transmission in Hospital Settings. 2011. [cited 2014 Feb 10]. http://apic.org/Resource_/EliminationGuideForm/16c7a44f-55fe-4c7b-819a-b9c5907eca72/File/APIC-MRSA-California.pdf 2009
  19. Health and Human Services. National action plan to prevent health care-associated infections: road map to elimination. 2014 [cited 2014 Feb 10]. http://www.health.gov/hai/prevent_hai.asp#hai_plan
  20. Dantes  R, Mu  Y, Belflower  R, Aragon  D, Dumyati  G, Harrison  LH, National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173:1970–8 .PubMedGoogle Scholar
  21. Whitney  CG, Farley  MM, Hadler  J, Harrison  LH, Lexau  C, Reingold  A, Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917–24. DOIPubMedGoogle Scholar
  22. Hampton  LM, Farley  MM, Schaffner  W, Thomas  A, Reingold  A, Harrison  LH, Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205:401–11 . DOIPubMedGoogle Scholar
  23. Dahesh  S, Hensler  ME, Van Sorge  NM, Gertz  RE Jr, Schrag  S, Nizet  V, Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother. 2008;52:2915–8. DOIPubMedGoogle Scholar
  24. Park  C, Nichols  M, Schrag  SJ. Two cases of invasive vancomycin-resistant group B Streptococcus infection. N Engl J Med. 2014;370:885–6. DOIPubMedGoogle Scholar
  25. Centers for Disease Control and Prevention. Emergence of fluoroquinolone-resistant Neisseria meningitides—Minnesota and North Dakota, 2007–2008. MMWR Morb Mortal Wkly Rep. 2008;57:173–5 .PubMedGoogle Scholar
  26. Rosenstein  NE, Stocker  SA, Popovic  T, Tenover  FC, Perkins  BA. Antimicrobial resistance of Neisseria meningitidis in the United States, 1997. Clin Infect Dis. 2000;30:212–3. DOIPubMedGoogle Scholar
  27. Bilukha  OO, Rosenstein  N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1–21 .PubMedGoogle Scholar
  28. Begier  EM, Barrett  NL, Mshar  PA, Johnson  DG, Hadler  JL. Gram-positive rod surveillance for early anthrax detection. Emerg Infect Dis. 2005;11:1483–6. DOIPubMedGoogle Scholar
  29. Louie  JK, Hacker  JK, Mark  J, Gavali  SS, Yagi  S, Espinosa  A, SARS and common viral infections. Emerg Infect Dis. 2004;10:1143–6. DOIPubMedGoogle Scholar
  30. Nelson  GE, Gershman  KA, Swerdlow  DL, Beall  BW, Moore  MR. Invasive pneumococcal disease and pandemic (H1N1) 2009, Denver, Colorado, USA. Emerg Infect Dis. 2012;18:208–16. DOIPubMedGoogle Scholar
  31. Kainer  MA, Reagan  DR, Nguyen  DB, Wiese  AD, Wise  ME, Ward  J, Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012;367:2194–203. DOIPubMedGoogle Scholar
  32. Hampton  LM, Zell  ER, Schrag  S, Cohen  AL. Sentinel versus population-based surveillance of pneumococcal conjugate vaccine effectiveness. Bull World Health Organ. 2012;90:568–77. DOIPubMedGoogle Scholar
  33. Van Beneden  CA, Lexau  C, Baughman  W, Barnes  B, Bennett  N, Cassidy  PM, Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniae. Emerg Infect Dis. 2003;9:1089–95. DOIPubMedGoogle Scholar
  34. Overhage  JM, Grannis  S, McDonald  CJ. A comparison of the completeness and timeliness of automated electronic laboratory reporting and spontaneous reporting of notifiable conditions. Am J Public Health. 2008;98:344–50. DOIPubMedGoogle Scholar
  35. Centers for Disease Control and Prevention. Automated detection and reporting of notifiable diseases using electronic medical records versus passive surveillance—Massachusetts, June 2006–July 2007. MMWR Morb Mortal Wkly Rep. 2008;57:373–6 .PubMedGoogle Scholar
  36. Kyaw  MH, Rose  CE Jr, Fry  AM, Singleton  JA, Moore  Z, Zell  ER, The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–86. DOIPubMedGoogle Scholar
  37. Blain  A, MacNeil  JR, Wang  X, Bennett  N, Farley  M, Harrison  LH, Invasive Haemophilus influenzae disease in adults >65 years, United States, 2011. Open Forum Infect Dis. 2014;1 [cited 2015 Jul 6]. http://ofid.oxfordjournals.org/content/1/2/ofu044.full.pdf+html
  38. Wortham  JM, Gershman  K, Baumback  J, Farley  M, Harrison  L, Lynfield  R, Racial disparities in invasive pneumococcal disease—United States, 1998–2009 [cited 2015 Jul 8]. Presented at: 61st Annual Epidemic Intelligence Service Conference; 2012 Apr 16–20; Atlanta, GA, USA. http://www.cdc.gov/eis/downloads/2012.eis.conference.pdf.
  39. Burton  DC, Flannery  B, Bennett  NM, Farley  MM, Gershman  K, Harrison  LH, Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. Am J Public Health. 2010;100:1904–11. DOIPubMedGoogle Scholar
  40. Soto  K, Petit  S, Hadler  JL. Changing disparities in invasive pneumococcal disease by socioeconomic status and race/ethnicity in Connecticut, 1998–2008. Public Health Rep. 2011;126(Suppl 3):81–8.PubMedGoogle Scholar

Main Article

Page created: August 12, 2015
Page updated: August 12, 2015
Page reviewed: August 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external